Lantern Pharma Inc.
LTRN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001763950
No open-market purchases or sales by Lantern Pharma Inc. insiders were filed in the last 90 days; 39 institutions reported holding it in 13F filings for Q2 2026, worth $12.0M in total; no superinvestor holds it.
13F holders, Q3 2023
Institutional positions in Lantern Pharma Inc. as of Sep 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 27
- +2 vs. Q2 2023
- Shares held
- 1.15M
- +1.81K (+0.2%) vs. Q2 2023
- Total value
- $3.93M
- −$2.56M (−39.5%) vs. Q2 2023
- New holders
- 3
- 5 more added
- Sold out
- 1
- 8 more reduced
Compare with Q2 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting LTRN on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 39 | $12.0M |
| Q1 2026 | 33 | $2.87M |
| Q4 2025 | 33 | $6.91M |
| Q3 2025 | 30 | $9.89M |
| Q2 2025 | 35 | $7.11M |
| Q1 2025 | 32 | $8.62M |
| Q4 2024 | 32 | $8.00M |
| Q3 2024 | 31 | $4.90M |
| Q2 2024 | 39 | $6.01M |
| Q1 2024 | 34 | $9.75M |
| Q4 2023 | 30 | $4.94M |
| Q3 2023 | 27 | $3.93M |
| Q2 2023 | 25 | $6.50M |
| Q1 2023 | 21 | $5.23M |
| Q4 2022 | 23 | $5.40M |
| Q3 2022 | 26 | $6.84M |
| Q2 2022 | 26 | $8.06M |
| Q1 2022 | 25 | $10.4M |
| Q4 2021 | 33 | $13.1M |
| Q3 2021 | 25 | $15.7M |
| Q2 2021 | 22 | $19.7M |
| Q1 2021 | 24 | $25.5M |
Institutions, Q3 2023
Shares, value and share of portfolio for each institution holding Lantern Pharma Inc.; share changes are against Q2 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Group Inc | 367,454 | $1.25M | 0.00% | 00.0% | Unchanged |
| GWM Advisors LLC | 170,031 | $579.8K | 0.01% | −1,434−0.8% | Reduced |
| Geode Capital Management, LLC | 95,036 | $324.1K | 0.00% | +5,010+5.6% | Added |
| Carlson Capital L P | 95,000 | $323.9K | 0.03% | 00.0% | Unchanged |
| CM Management, LLC | 75,000 | $255.8K | 0.27% | 00.0% | Unchanged |
| Redmond Asset Management, LLC | 46,506 | $158.6K | 0.06% | −98−0.2% | Reduced |
| Renaissance Technologies LLC | 38,100 | $130.0K | 0.00% | −6,800−15.1% | Reduced |
| Pathway Financial Advisors LLC | 32,771 | $111.7K | 0.04% | +18,770+134.1% | Added |
| Citadel Advisors LLC | 30,632 | $104.5K | 0.00% | +5,895+23.8% | Added |
| Horizon Kinetics Asset Management LLC | 30,000 | $102.3K | 0.00% | 00.0% | Unchanged |
| State Street Corp | 27,752 | $94.6K | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 27,000 | $92.1K | 0.00% | 00.0% | Unchanged |
| Bank of New York Mellon Corp | 26,481 | $90.3K | 0.00% | +10.0% | Added |
| BlackRock Inc. | 20,148 | $68.7K | 0.00% | −651−3.1% | Reduced |
| Sigma Planning Corp | 18,125 | $61.8K | 0.00% | 00.0% | Unchanged |
| Meridian Wealth Management, LLC | 16,660 | $56.8K | 0.00% | +16,660 | New |
| Commonwealth Equity Services, LLC | 15,368 | $52.0K | 0.00% | −1,445−8.6% | Reduced |
| Northern Trust Corp | 12,593 | $42.9K | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 4,492 | $15.3K | 0.00% | +4+0.1% | Added |
| Wolff Wiese Magana LLC | 2,200 | $7.50K | 0.01% | −22,945−91.3% | Reduced |
| Tower Research Capital LLC (TRC) | 1,857 | $6.33K | 0.00% | −482−20.6% | Reduced |
| Rhumbline Advisers | 228 | $777 | 0.00% | 00.0% | Unchanged |
| Advisor Group Holdings, Inc. | 200 | $682 | 0.00% | 00.0% | Unchanged |
| Allworth Financial LP | 100 | $341 | 0.00% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 9 | $31 | 0.00% | +9 | New |
| Qube Research & Technologies Ltd | 2 | $7 | 0.00% | +2 | New |
| Royal Bank of Canada | 106 | $0 | 0.00% | −100−48.5% | Reduced |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −10,581−100.0% | Sold out |